Investment case
Eli Lilly and Company
LLY · 126 developments mapped · last assessed 2026-09-29
Market Ontology has mapped 126 macro, policy, and market developments to Eli Lilly and Company since 2026-08-18. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for LLY yet, so no modelled value is shown. The LLY valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run LLY on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Eli Lilly Discontinues Sub-Par GLP-1 Candidate to Refocus Capital on Next-Gen Formulations
Strategic capital allocation, R&D efficiency, pipeline optimization
· Moves r&d spend efficiency, probability of success for pipeline assets, future revenue growth from next gen products
- Main threat
Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli Lilly
Increased direct competition in the GLP-1 weight-loss market, particularly from a new oral formulation with a potentially aggressive pricing strategy.
· Moves potential erosion of market share in glp 1 segment, pressure on pricing for existing glp 1 products, increased marketing and r&d expenses to counter competition
- Open question
Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D Reallocation
Strategic R&D reallocation, pipeline efficiency, and market perception of future growth drivers.
· Moves probability of success for early stage pipeline assets, future r&d efficiency and return on investment, long term growth rate for cardiometabolic franchise
What changed, by assumption
- 2026-09-28Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D Reallocation
- 2026-09-27Eli Lilly Drops Experimental Obesity Candidate; Incretins Exceed 65% of Total Revenue
- 2026-09-28Eli Lilly drops pipeline GLP-1 candidate on efficacy while maintaining franchise lead
- 2026-09-28Eli Lilly discontinues pipeline GLP-1 candidate following efficacy review
- 2026-09-28Eli Lilly Discontinues Sub-Par GLP-1 Candidate to Refocus Capital on Next-Gen Formulations
- 2026-09-28Eli Lilly Drops Experimental GLP-1 Candidate Following Subpar Efficacy Data
- 2026-09-27Eli Lilly Drops Experimental Obesity Candidate While Core GLP-1s Exceed 65% of Revenue
- 2026-09-27Eli Lilly Discontinues Developmental GLP-1 Candidate Over Efficacy Standards
- 2026-09-27Hangzhou Global Open-Source AI Challenge Awards 1M RMB to Peptide Algorithm
- 2026-09-23Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli Lilly
- 2026-09-23Novo Rebrands to 'Novo' and Launches Oral GLP-1 Pill in Obesity Market Push
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-06 | Margin | Bullish | Surging demand for high-margin GLP-1 agonists (Mounjaro/Zepbound) is driving margin expansion and earnings revisions. | 0.95 |
| 2026-07-22 | Revenue | Bullish | Expansion of GLP-1 TAM into alcohol use disorder treatment. | 0.80 |
| 2026-07-13 | Revenue | Bullish | Company raised 2026 guidance to $82-85B based on Mounjaro and Zepbound growth. | 1.00 |
| 2026-06-17 | Revenue | Bullish | GLP-1 market projected to reach $95.3B by 2035 with a 12.1% CAGR, driven by oral formulations. | 0.90 |
| 2026-06-12 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-06-12 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-06-12 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-29 | AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer | Bearish | 1-3m | 0.30 |
| 2026-09-29 | AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung Cancer | watch | 1-5y | 0.30 |
| 2026-09-28 | Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D Reallocation | mixed | 1-3m | 0.70 |
| 2026-09-28 | HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830 | watch | 1-5y | 0.20 |
| 2026-09-28 | Eli Lilly discontinues pipeline GLP-1 candidate following efficacy review | mixed | 1-3m | 0.30 |
| 2026-09-28 | Eli Lilly Discontinues Experimental GLP-1 Candidate Following Efficacy Review | Bullish | 1-3m | 0.60 |
| 2026-09-28 | HUTCHMED doses first patient in Phase Ia trial of KRAS-EGFR conjugate HMPL-A830 | watch | 1-5y | 0.10 |
| 2026-09-28 | Eli Lilly drops pipeline GLP-1 candidate on efficacy while maintaining franchise lead | mixed | 1-3m | 0.40 |
| 2026-09-28 | Eli Lilly Discontinues Early-Stage GLP-1 Candidate Following Efficacy Review | mixed | 1-3m | 0.30 |
| 2026-09-28 | Eli Lilly Drops Experimental GLP-1 Candidate as Core Incretin Portfolio Reaches 65% of Sales | mixed | 1-3m | 0.60 |
| 2026-09-28 | HUTCHMED and GSK Initiate Phase Ia Trial for KRAS-EGFR Conjugate Therapy | watch | 3-12m | 0.20 |
| 2026-09-28 | Eli Lilly Discontinues Sub-Par GLP-1 Candidate to Refocus Capital on Next-Gen Formulations | Bullish | 1-3m | 0.70 |